Tityus serrulatus scorpion venom as a potential drug source for Chagas' disease Trypanocidal and immunomodulatory activity

Tityus serrulatus scorpion venom as a potential drug source for Chagas' disease : Trypanocidal and immunomodulatory activity

Copyright © 2021 Elsevier Inc. All rights reserved.

Bibliographische Detailangaben
Veröffentlicht in:Clinical immunology (Orlando, Fla.). - 1999. - 226(2021) vom: 15. Mai, Seite 108713
1. Verfasser: Pimentel, Pollyana Maria de Oliveira (VerfasserIn)
Weitere Verfasser: de Assis, Diego Rodney Rodrigues, Gualdrón-Lopez, Melisa, Barroso, Andréia, Brant, Fátima, Leite, Paulo Gaio, de Lima Oliveira, Bruno Cabral, Esper, Lisia, McKinnie, Shaun M K, Vederas, John C, do Nascimento Cordeiro, Marta, Dos Reis, Pablo Victor Mendes, Teixeira, Mauro Martins, de Castro Pimenta, Adriano Monteiro, Borges, Márcia Helena, de Lima, Maria Elena, Machado, Fabiana Simão
Format: Online-Aufsatz
Sprache:English
Veröffentlicht: 2021
Zugriff auf das übergeordnete Werk:Clinical immunology (Orlando, Fla.)
Schlagworte:Journal Article Research Support, Non-U.S. Gov't Infectious disease Macrophage Mitogen-activated protein kinase (MAPK) Peptides Tityus serrulatus Trypanosoma cruzi Interleukin-6 Scorpion Venoms mehr... Tumor Necrosis Factors Nitric Oxide 31C4KY9ESH
LEADER 01000naa a22002652 4500
001 NLM322683017
003 DE-627
005 20231225182546.0
007 cr uuu---uuuuu
008 231225s2021 xx |||||o 00| ||eng c
024 7 |a 10.1016/j.clim.2021.108713  |2 doi 
028 5 2 |a pubmed24n1075.xml 
035 |a (DE-627)NLM322683017 
035 |a (NLM)33711450 
035 |a (PII)S1521-6616(21)00050-4 
040 |a DE-627  |b ger  |c DE-627  |e rakwb 
041 |a eng 
100 1 |a Pimentel, Pollyana Maria de Oliveira  |e verfasserin  |4 aut 
245 1 0 |a Tityus serrulatus scorpion venom as a potential drug source for Chagas' disease  |b Trypanocidal and immunomodulatory activity 
264 1 |c 2021 
336 |a Text  |b txt  |2 rdacontent 
337 |a ƒaComputermedien  |b c  |2 rdamedia 
338 |a ƒa Online-Ressource  |b cr  |2 rdacarrier 
500 |a Date Completed 24.06.2021 
500 |a Date Revised 24.06.2021 
500 |a published: Print-Electronic 
500 |a Citation Status MEDLINE 
520 |a Copyright © 2021 Elsevier Inc. All rights reserved. 
520 |a Current chemical therapies for Chagas Disease (CD) lack ability to clear Trypanosoma cruzi (Tc) parasites and cause severe side effects, making search for new strategies extremely necessary. We evaluated the action of Tityus serrulatus venom (TsV) components during Tc infection. TsV treatment increased nitric oxide and pro-inflammatory cytokine production by Tc-infected macrophages (MØ), decreased intracellular parasite replication and trypomastigotes release, also triggering ERK1/2, JNK1/2 and p38 activation. Ts7 demonstrated the highest anti-Tc activity, inducing high levels of TNF and IL-6 in infected MØ. TsV/Ts7 presented synergistic effect on p38 activation when incubated with Tc antigen. KPP-treatment of MØ also decreased trypomastigotes releasing, partially due to p38 activation. TsV/Ts7-pre-incubation of Tc demonstrated a direct effect on parasite decreasing MØ-trypomastigotes releasing. In vivo KPP-treatment of Tc-infected mice resulted in decreased parasitemia. Summarizing, this study opens perspectives for new bioactive molecules as CD-therapeutic treatment, demonstrating the TsV/Ts7/KPP-trypanocidal and immunomodulatory activity during Tc infection 
650 4 |a Journal Article 
650 4 |a Research Support, Non-U.S. Gov't 
650 4 |a Infectious disease 
650 4 |a Macrophage 
650 4 |a Mitogen-activated protein kinase (MAPK) 
650 4 |a Peptides 
650 4 |a Tityus serrulatus 
650 4 |a Trypanosoma cruzi 
650 7 |a Interleukin-6  |2 NLM 
650 7 |a Scorpion Venoms  |2 NLM 
650 7 |a Tumor Necrosis Factors  |2 NLM 
650 7 |a Nitric Oxide  |2 NLM 
650 7 |a 31C4KY9ESH  |2 NLM 
700 1 |a de Assis, Diego Rodney Rodrigues  |e verfasserin  |4 aut 
700 1 |a Gualdrón-Lopez, Melisa  |e verfasserin  |4 aut 
700 1 |a Barroso, Andréia  |e verfasserin  |4 aut 
700 1 |a Brant, Fátima  |e verfasserin  |4 aut 
700 1 |a Leite, Paulo Gaio  |e verfasserin  |4 aut 
700 1 |a de Lima Oliveira, Bruno Cabral  |e verfasserin  |4 aut 
700 1 |a Esper, Lisia  |e verfasserin  |4 aut 
700 1 |a McKinnie, Shaun M K  |e verfasserin  |4 aut 
700 1 |a Vederas, John C  |e verfasserin  |4 aut 
700 1 |a do Nascimento Cordeiro, Marta  |e verfasserin  |4 aut 
700 1 |a Dos Reis, Pablo Victor Mendes  |e verfasserin  |4 aut 
700 1 |a Teixeira, Mauro Martins  |e verfasserin  |4 aut 
700 1 |a de Castro Pimenta, Adriano Monteiro  |e verfasserin  |4 aut 
700 1 |a Borges, Márcia Helena  |e verfasserin  |4 aut 
700 1 |a de Lima, Maria Elena  |e verfasserin  |4 aut 
700 1 |a Machado, Fabiana Simão  |e verfasserin  |4 aut 
773 0 8 |i Enthalten in  |t Clinical immunology (Orlando, Fla.)  |d 1999  |g 226(2021) vom: 15. Mai, Seite 108713  |w (DE-627)NLM098196855  |x 1521-7035  |7 nnns 
773 1 8 |g volume:226  |g year:2021  |g day:15  |g month:05  |g pages:108713 
856 4 0 |u http://dx.doi.org/10.1016/j.clim.2021.108713  |3 Volltext 
912 |a GBV_USEFLAG_A 
912 |a SYSFLAG_A 
912 |a GBV_NLM 
912 |a GBV_ILN_11 
912 |a GBV_ILN_24 
912 |a GBV_ILN_350 
951 |a AR 
952 |d 226  |j 2021  |b 15  |c 05  |h 108713